Literature DB >> 8279709

Synovial-type (group II) phospholipase A2 human seminal plasma.

T J Nevalainen1, K M Meri, M Niemi.   

Abstract

Phospholipase A2 (PLA2) was analysed in seminal plasma of fertile, subfertile, and vasectomized men as well as in prostatic secretion and tissue. Immunological cross-reactivity was observed between synovial-type PLA2 antiserum and the enzyme present in seminal plasma. There was a highly significant correlation between the concentration of the synovial-type PLA2, as measured by a time-resolved fluoroimmunoassay and the catalytic activity of the PLA2. The results show that the PLA2 content in human seminal plasma is very high (approximately 1000 times of that present in blood plasma) and that the enzyme belongs to the synovial-type group II phospholipase A2. The results also indicate that the enzyme is secreted by the prostate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279709     DOI: 10.1111/j.1439-0272.1993.tb02742.x

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  11 in total

1.  Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears.

Authors:  X D Qu; R I Lehrer
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 2.  Molecular determinants of bacterial sensitivity and resistance to mammalian Group IIA phospholipase A2.

Authors:  Jerrold P Weiss
Journal:  Biochim Biophys Acta       Date:  2015-06-14

3.  Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis.

Authors:  Suet Y Leung; Xin Chen; Kent M Chu; Siu T Yuen; Jonathan Mathy; Jiafu Ji; Annie S Y Chan; Rui Li; Simon Law; Olga G Troyanskaya; I-Ping Tu; John Wong; Samuel So; David Botstein; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

4.  Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.

Authors:  Jiazhong Jiang; Blake Lee Neubauer; Jeremy R Graff; Marcio Chedid; James E Thomas; Neal W Roehm; Shaobo Zhang; George J Eckert; Michael O Koch; John N Eble; Liang Cheng
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

5.  Antibacterial properties of chicken intestinal phospholipase A2.

Authors:  Aida Karray; Yassine Ben Ali; Youssef Gargouri; Sofiane Bezzine
Journal:  Lipids Health Dis       Date:  2011-01-12       Impact factor: 3.876

6.  Wall teichoic acid deficiency in Staphylococcus aureus confers selective resistance to mammalian group IIA phospholipase A(2) and human beta-defensin 3.

Authors:  Tomaz Koprivnjak; Christopher Weidenmaier; Andreas Peschel; Jerrold P Weiss
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

7.  Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2.

Authors:  Y Weinrauch; C Abad; N S Liang; S F Lowry; J Weiss
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

8.  Secreted phospholipase A2 is increased in meconium-stained amniotic fluid of term gestations: potential implications for the genesis of meconium aspiration syndrome.

Authors:  Roberto Romero; Bo Hyun Yoon; Piya Chaemsaithong; Josef Cortez; Chan-Wook Park; Rogelio Gonzalez; Ernesto Behnke; Sonia S Hassan; Francesca Gotsch; Lami Yeo; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-01-06

9.  The major bactericidal activity of human seminal plasma is zinc-dependent and derived from fragmentation of the semenogelins.

Authors:  Anneli M L Edström; Johan Malm; Birgitta Frohm; Julie A Martellini; Aleksander Giwercman; Matthias Mörgelin; Alexander M Cole; Ole E Sørensen
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

10.  Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate.

Authors:  D S Grass; R H Felkner; M Y Chiang; R E Wallace; T J Nevalainen; C F Bennett; M E Swanson
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.